Century Therapeutics, Inc. Cash and Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
Century Therapeutics, Inc. (IPSC) reported Cash and Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of $56.60 million for the 6-month period ending 2022-06-30, per its 10-Q filed 2022-08-11.
Discontinued › Cash Flow
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2022-08-11
- Century Therapeutics, Inc. cash and cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2022-03-31 was $69.59M, a 33.14% increase year-over-year.
- Century Therapeutics, Inc. cash and cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2021-03-31 was $52.27M.
- Century Therapeutics, Inc. cash and cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2021 was $30.43M.
- Century Therapeutics, Inc. cash and cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2020 was -$16.34M.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash and Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash and Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash and Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2022-06-30 | $56.60M 10-Q · filed 2022-08-11 | |||
| 2022-03-31 | $69.59M 10-Q · filed 2022-05-16 | |||
| 2021-12-31 | $30.43M 10-K · filed 2022-03-17 | |||
| 2021-09-30 | $75.28M 10-Q · filed 2021-11-10 | |||
| 2021-06-30 | $246.78M 10-Q · filed 2022-08-11 | |||
| 2021-03-31 | $52.27M 10-Q · filed 2022-05-16 | |||
| 2020-12-31 | -$16.34M 10-K · filed 2022-03-17 | |||
| 2020-09-30 | -$20.43M 10-Q · filed 2021-11-10 | |||
| 2020-06-30 | -$21.29M 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |